Established in 1991, Mankind Pharma Limited is a prominent player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of pharmaceutical formulations and consumer healthcare products.
Within India, the company operates across various therapeutic domains, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
With a portfolio of more than 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, the company serves diverse medical needs.
Mankind Pharma boasts one of the most expansive distribution networks of medical representatives in India’s pharmaceutical market. Over 80% of Indian doctors prefer their formulations, contributing to their ranking as the 4th highest in domestic sales during FY2022.
The company has garnered numerous accolades, including the Best of Bharat Award 2022 by exchange4media, and a Silver Medal from the National Awards for Manufacturing Competitiveness Assessment 2021 by the International Research Institute for Manufacturing.
With an extensive marketing reach spanning the entire nation, Mankind Pharma employs a dedicated team of 11,691 medical representatives and 3,561 field managers as of December 31, 2022. Operating from 25 manufacturing facilities across India, the company boasts a manufacturing workforce of 4,121 as of the same date.
Supported by a team of over 600 scientists, the company houses an in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana, and Thane, Maharashtra, contributing to their ongoing growth and innovation.
Mankind Pharma Limited Stock Quote #
- Open: ₹1,845.00
- High – Low: ₹1,850.00 – ₹1,816.05
- Previous Close: ₹1,841.60
- Total Traded Value: 2,27,997
- 52 Weeks High: ₹1,949.00 (Jul 24, 2023)
- 52 Weeks Low: ₹1,242.00 (May 22, 2023)
- Updated On: Aug 11, 2023 4:00 PM
IPO Details #
Mankind Pharma IPO is a Book Built Issue. The IPO total issue size is Rs 4,326.36 Cr. The Mankind Pharma IPO price is ₹1026 to ₹1080 per share. The IPO will list on BSE, NSE.
| IPO Date | Apr 25, 2023 to Apr 27, 2023 |
| Listing Date | May 9, 2023 |
| Face Value | ₹1 per share |
| Price | ₹1026 to ₹1080 per share |
| Lot Size | 13 Shares |
| Total Issue Size | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Offer for Sale | 40,058,844 shares of ₹1 (aggregating up to ₹4,326.36 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
IPO Reservation #
Mankind Pharma IPO a total of 40,058,844 shares are offered. QIB: 8,011,769 (20.00%), RII: 14,020,596 (35.00%), NII: 6,008,827 (15.00%).
| Anchor Investor Shares Offered | 12,017,652 (30.00%) |
| QIB Shares Offered | 8,011,769 (20.00%) |
| NII (HNI) Shares Offered | 6,008,827 (15.00%) |
| Retail Shares Offered | 14,020,596 (35.00%) |
| Total Shares Offered | 40,058,844 (100%) |
Mankind Pharma IPO Anchor Investors Details #
It raises Rs 1,297.91 crore from anchor investors. Mankind Pharma IPO Anchor bid date is Apr 24, 2023. Mankind Pharma IPO Anchor Investors list
| Bid Date | Apr 24, 2023 |
| Shares Offered | 12,017,652 |
| Anchor Portion Size (In Cr.) | 1,297.91 |
| Anchor lock-in period end date for 50% shares (30 Days) | Jun 14, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sep 8, 2023 |
Mankind Pharma IPO Timetable (Tentative) #
Mankind Pharma IPO opens on Apr 25, 2023, and closes on Apr 27, 2023.
| IPO Open Date | Tuesday, 25 April 2023 |
| IPO Close Date | Thursday, 27 April 2023 |
| Basis of Allotment | Wednesday, 3 May 2023 |
| Initiation of Refunds | Thursday, 4 May 2023 |
| Credit of Shares to Demat | Friday, 5 May 2023 |
| Listing Date | Tuesday, 9 May 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on Apr 27, 2023 |
Mankind Pharma IPO Lot Size #
The minimum lot size of this Mankind Pharma IPO is 13 shares required is ₹14,040.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹196,560 |
| S-HNI (Min) | 15 | 195 | ₹210,600 |
| S-HNI (Max) | 71 | 923 | ₹996,840 |
| B-HNI (Min) | 72 | 936 | ₹1,010,880 |
| Lot Size Calculator | |||
Mankind Pharma IPO Promoter Holding #
Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust are the company promoters.
| Pre Issue Share Holding | 79.00% |
| Post Issue Share Holding | 76.50% |
Company Financials #
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 5,073.29 | 5,975.65 | 1,056.15 | 3,485.31 | 3,436.34 | 126.92 |
| 31-Mar-21 | 6,372.63 | 6,385.38 | 1,293.03 | 4,722.00 | 4,674.39 | 234.53 |
| 31-Dec-21 | 8,043.88 | 6,218.29 | 1,260.24 | 5,965.46 | 5,916.86 | 268.70 |
| 31-Mar-22 | 9,147.74 | 7,977.58 | 1,452.96 | 6,155.23 | 6,106.06 | 868.03 |
| 31-Dec-22 | 9,273.75 | 6,777.82 | 1,015.98 | 7,145.89 | 7,094.12 | 167.93 |
| Amount in ₹ Crore | ||||||
Key Performance Indicator #
Mankind Pharma IPO Market Cap is Rs 43263.6 Cr and P/E (x) is 32.5.
| KPI | Values |
|---|---|
| P/E (x) | 32.5 |
| Market Cap (₹ Cr.) | 43263.6 |
| ROE | 27.60% |
| ROCE | 26.10% |
| EPS (Rs) | 33.2 |
| RoNW | 27.70% |
Objects of the Issue #
The company will not receive any proceeds from the offer and all the offer proceeds will be received by the selling shareholders, in proportion to the offered shares sold by the respective selling shareholders as part of the offer.
Mankind Pharma IPO Subscription Status (Bidding Detail) #
The Mankind Pharma IPO is subscribed 15.32 times on Apr 27, 2023 7:02:00 PM. The public issue subscribed 0.92 times in the retail category, 49.16 times in the QIB category, and 3.80 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 49.16 |
| NII | 3.80 |
| bNII (bids above ₹10L) | 4.99 |
| sNII (bids below ₹10L) | 1.41 |
| Retail | 0.92 |
| Total | 15.32 |
Total Application : 462,789 (0.43 times)
Mankind Pharma IPO Prospectus #
Mankind Pharma IPO Listing Details #
| Listing Date | May 9, 2023 |
| BSE Script Code | 543904 |
| NSE Symbol | MANKIND |
| ISIN | INE634S01028 |
| Final Issue Price | ₹1080 per share |
Listing Day Trading Information #
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹1,080.00 |
| ₹1,300.00 |
| ₹1,300.00 |
| ₹1,430.00 |
| ₹1,424.05 |
| NSE |
|---|
| ₹1,080.00 |
| ₹1,300.00 |
| ₹1,300.00 |
| ₹1,430.00 |
| ₹1,080.00 |
Company Contact Information #
208, Okhla Industrial Estate
Phase-III,
New Delhi 110020
Phone: +91 11 4684 6700
Email: investors@mankindpharma.com
Website: https://www.mankindpharma.com/
Mankind Pharma IPO Registrar #
Phone: 04067162222, 04079611000
Email: mankind.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Mankind Pharma IPO Lead Manager(s) #
- Kotak Mahindra Capital Company Limited (Past IPO Performance)
- Axis Capital Limited (Past IPO Performance)
- IIFL Securities Ltd (Past IPO Performance)
- Jefferies India Private Limited (Past IPO Performance)
- J.P. Morgan India Private Limited (Past IPO Performance)
FAQs #
What is the price range for Mankind Pharma IPO shares? #
The Mankind Pharma IPO price range is ₹1026 to ₹1080 per share.
When is the IPO open and closing dates for Mankind Pharma? #
The IPO is open from April 25, 2023, to April 27, 2023.
How many shares are being offered in the Mankind Pharma IPO? #
The IPO offers a total of 40,058,844 equity shares.
What is the subscription status of Mankind Pharma IPO? #
The IPO offers 14,020,596 shares to retail investors and 8,011,769 shares to qualified institutional buyers.
Is there a basis of allotment status available for Mankind Pharma IPO? #
Yes, the equity shares of Mankind Pharma are proposed to be listed on the Main Board of the stock exchanges.
Please note that the above information is based on the data available and may be subject to change.
